Kazia Therapeutics Limited
Biotechnology Research • 
Sydney, New South Wales, Australia • 11-20 Employees
Company overview
| Headquarters | 300 Barangaroo Ave, L24, Barangaroo, New South Wales 2000, AU |
| Phone number | +61294724100 |
| Websites | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 1994 |
| Employees | 11-20 |
| Socials |
Key Contacts at Kazia Therapeutics Limited
Bryce Carmine
Non Executive Director
Michael Fitzgerald
Program Director
John Friend
Chief Executive Officer
Dominic Capone
Program Director/ Executive Director Clinical Operations
Steven Coffey
Director
David Cain
Director Cmc
Kazia Therapeutics Limited Email Formats
Kazia Therapeutics Limited uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@kaziatherapeutics.com), used 47.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@kaziatherapeutics.com | 47.1% |
{first name}.{last name} | john.doe@kaziatherapeutics.com | 52.9% |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company. Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults. There are few treatment options for sufferers of GBM and around 65% of sufferers do not respond to currently available treatments. The condition affects around 133,000 people globally per annum and the potential addressable market is worth more than US$1 billion. Kazia’s drug paxalisib, commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. Kazia is also developing EVT801, , a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data for EVT801 has shown it to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents. A phase I study is expected to begin in CY2021. Competitive Advantages: - Lead program, paxalisib, sourced from the world’s most successful cancer drug developer, Genentech - Experienced team with extensive backgrounds in big pharma and biotech - Around 65% of GBM sufferers do not respond to current treatments - Multiple shots on goal with collaborations progressing in other cancers; largely funded by participating hospitals
Kazia Therapeutics Limited revenue & valuation
| Annual revenue | $11,500,000 |
| Revenue per employee | $817,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $36,600,000 |
| Total funding | $3,800,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Kazia Therapeutics Limited has 5 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Kazia Therapeutics Limited's funding history, including investment rounds, total capital raised, and key backers.
Kazia Therapeutics Limited Tech Stack
Discover the technologies and tools that power Kazia Therapeutics Limited's digital infrastructure, from frameworks to analytics platforms.
CDN
PaaS
Security
JavaScript libraries
Tag managers
JavaScript libraries
Security
JavaScript libraries
Miscellaneous
Font scripts
JavaScript libraries
UI frameworks
Canada
United Arab Emirates
Antigua and Barbuda
Frequently asked questions
4.8
40,000 users
